Poster Session A  
Monday, September 29, 2014  
12:00 p.m.-2:00 p.m.  
Armstrong Ballroom

Biomarkers and Early Detection Research: Bioinformatics and Omics

A01 Genome-wide changes in expression of small RNAs in human testis cancer tissue. Trine Rounge, Cancer Registry of Norway, Oslo, Norway.

A02 Integrative analysis identifies differential miRNA expression in HPV-positive head and neck squamous cell carcinoma including mir-9 overexpression and corresponding downregulation of the target YAP1. Claudia Heymach, University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Biomarkers and Early Detection Research: Biomarkers of Cancer Susceptibility

A03 ERβ expression and breast cancer risk prediction for women with atypias. Tina Hieken, Mayo Clinic, Rochester, MN, United States.

A04 Menopausal vasomotor symptoms and incident breast cancer risk in the Study of Women's Health Across the Nation. Vicki Hart, University of Massachusetts Amherst, Amherst, MA, United States.

A05 Menopausal vasomotor symptoms and mammographic density in the Study of Women's Health Across the Nation. Vicki Hart, University of Massachusetts Amherst, Amherst, MA, United States.

A06 Elucidating the associations of inflammation with cancer risk and mortality using an inflammatory score: Results from a prospective cohort study. Adetunji Toriola, Washington University School of Medicine, St. Louis, MO, United States.

A07 Methylation of RARB in pre-diagnosis benign tissue and risk of disease progression in men subsequently diagnosed with prostate cancer. Benjamin Rybicki, Henry Ford Hospital, Detroit, United States.

A08 Lipid biomarkers and cancer risk: Long term observational follow-up of cancer in the Women's Health Study. Paulette Chandler, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.

A09 The relationship between DNA methylation in one-carbon metabolism genes and colorectal adenoma risk. Vikki Ho, University of Montreal Hospital Research Centre, Montreal, Quebec, Canada.

Biomarkers and Early Detection Research: Biomarkers of Carcinogen Exposure

A10 Exposure to heterocyclic aromatic amines, genetic susceptibility and bulky DNA adduct levels in blood leukocytes. Vikki Ho, University of Montreal Hospital Research Centre, Montreal, Quebec, Canada.
Biomarkers and Early Detection Research: Biomarkers of Premalignant Lesions

A11 Airway gene expression indicates an increase in oxidative phosphorylation in the field of injury of individuals with premalignant lesions. Sarah Mazzilli, Boston University, Boston, MA, United States.

A12 Identification of novel candidate serum metabolite biomarkers for distinguishing between gastro-esophageal reflux disease, Barrett’s esophagus, and high-grade dysplasia/esophageal adenocarcinoma. Matthew Buas, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.

Biomarkers and Early Detection Research: Imaging


Biomarkers and Early Detection Research: Molecular Diagnostics

A14 Role of miRNAs as biomarker for the anti-tumoral activity of the plant derived polyphenol Curcumin. Beatrice Bachmeier, Inst. of Laboratory Medicine, Ludwig-Maximilians-University, Munich, Germany.

Biomarkers and Early Detection Research: Other

A15 Immunohistochemical patterns of the breast developmental gene, ELF5, reveals differential expression in high grade hormone receptor negative clinical breast cancer. Teresa Rose-Hellekant, University of Minnesota Medical School, Duluth, MN, United States.

Clinical Prevention Trials (by Organ Site): Breast Cancer


Clinical Prevention Trials (by Organ Site): Head and Neck Cancers

A19 Enhanced curcumin bioavailability through localized microgranular formulation in healthy and cancer treatment cohorts. Brian Latimer, LSUHSC, Shreveport, United States.

Clinical Prevention Trials (by Organ Site): Prostate and Other Genitourinary Tract Cancers

A20 A phase II randomized, presurgical placebo-controlled trial of polyphenon E in bladder cancer patients to evaluate bladder tissue levels of EGCG and biomarkers of growth and apoptosis. Jason Gee, Lahey Hospital and Medical Center, Burlington, MA, United States.
Metformin Prevention and Treatment Trials

A21 A Phase IIa trial of Metformin for colorectal cancer risk reduction among patients with a history of colorectal adenomas and elevated body mass index. Jason Zell, University of California Irvine, Irvine, CA, United States.

A22 Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial. Andrea DeCensi, E.O. Ospedali Galliera, Genoa, GE, Italy.

A23 Cancer outcomes in the diabetes prevention program outcomes study. Brandy Heckman-Stodlard, National Cancer Institute, Rockville, MD, United States.

A24 Integration of tumor metabolomics, cancer genome sequencing and dynamic functional imaging to assess the metabolic effects of metformin in breast cancer. A. Harris, University of Oxford, Oxford, United Kingdom.

Epidemiology/Lifestyle Factors: Behavioral Epidemiology

A25 Television watching, other sedentary behaviors and colorectal cancer survival in men. Yin Cao, Harvard University, Boston, MA, United States.

A26 Relative influence of home and school environments on specific dietary behaviors among postpartum, high-risk teens. Megan Clarke, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.

Epidemiology/Lifestyle Factors: Cancer in Aging Populations


Epidemiology/Lifestyle Factors: Cancer in Minority and Medically Underserved Populations


A29 Racial disparities in prostate cancer: Estimating the role of diet, lifestyle, and genetic factors among African-American and Caucasian-American men. Sam Peisch, Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States.

A30 Breast cancer Family-based Intervention Trial. Katherine Infante, Columbia University Medical Center, New York, NY, United States.

Epidemiology/Lifestyle Factors: Diet and Cancer

A31 Correlations between diet, gut microbiota and epithelial methylation pattern with CRC risk. Volker Mai, University of Florida, Gainesville, FL, United States.

A32 Dairy intake in relation to disease-specific and total mortality after prostate cancer diagnosis. Meng Yang, Department of Nutrition, Harvard School of Public Health, Boston, MA, United States.

A33 Pizza and pasta consumption levels in relation to lycopene and other antioxidant nutrients status among a low-income population in Southeast USA. Yuan Zhou, Meharry Medical College, Nashville, Tennessee, United States.
A34 Association of nut consumption and lung cancer risk in a large population-based case-control study. Tram Lam, National Cancer Institute, Rockville, Maryland, United States.


Epidemiology/Lifestyle Factors: Exercise and Prevention

A36 Recreational physical activity and the risk of pancreatic cancer in the California Teachers Study. Kayo Togawa, Beckman Research Institute of City of Hope, Duarte, California, United States.

A37 Feasibility of repeat physical activity measurement among colorectal cancer patients by accelerometry and associations with plasma 25(OH)D levels. Stephanie Tosic, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany.

Epidemiology/Lifestyle Factors: Familial and Genetic Epidemiology

A38 Role of MC1R variants in childhood and adolescent melanoma. Sara Raimondi, European Institute of Oncology, Milan, Italy.

A39 Meta-analysis on Vitamin D Receptor polymorphisms and colorectal cancer risk. Sara Gandini, European Institute of Oncology, Milan, Italy.

A40 Multiple locations on 8q24 and 6p21-22 and rare variants associated with gastric cancer susceptibility in a Korean population. Jeongseon Kim, National Cancer Center, Goyang, Rep. of Korea.

A41 Known susceptibility SNPs for sporadic prostate cancer play a similar role in hereditary prostate cancer. Lambertus Kiemeney, Radboudumc, Nijmegen, Netherlands.

Epidemiology/Lifestyle Factors: General Epidemiology and Biostatistics

A42 Adolescent inflammation and body mass index in relation to colorectal cancer risk. Elizabeth Kantor, Harvard School of Public Health, Boston, MA, United States.

A43 Population attributable risk of postmenopausal breast cancer according to known and modifiable breast cancer risk factors. Rulla Tamimi, Brigham and Women's Hospital, Boston, MA, United States.

Epidemiology/Lifestyle Factors: Obesity, Metabolism, and Cancer

A44 Association between BMI at treatment initiation and cancer survival across multiple SWOG trials. Heather Greenlee, Columbia University, New York, NY, United States.

A45 The association between type 2 diabetes mellitus and incidence of renal cell carcinoma (RCC) and fatal RCC in two prospective cohorts. Rebecca Graff, Harvard School of Public Health, Boston, MA, United States.

A46 Body mass index, waist circumference, and the risk of colorectal adenomas: Black women's health study. Chiranjeev Dash, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, United States.
Epidemiology/Lifestyle Factors: Tobacco and Cancer

A47 Meta-analysis of MTHFR polymorphisms in lung cancer: Population health and mutations in the world. Hsiao-Ling Chen, Department of Nursing, College of Medicine, National Taiwan University, Taipei, Taiwan.

Epidemiology/Lifestyle Factors: Other Molecular Epidemiology

A48 Serum biomarkers of habitual coffee consumption may provide insight into the mechanism underlying the association between coffee consumption and colorectal cancer. Kristin Guertin, Division of Cancer Epidemiology & Genetics, National Cancer Institute, Rockville, MD, United States.

A49 Meta-analysis of vitamin D–binding protein and cancer risk. Sara Gandini, European Institute of Oncology, Milan, Italy.

Epidemiology/Lifestyle Factors: Other Risk Factors

A50 Impact of indoor tanning and MC1R genotype on basal cell carcinoma risk in young people. Susan Mayne, Yale School of Public Health, New Haven, CT, United States.

A51 Mammographic breast density and breast cancer risk: Interactions of percent density, absolute dense and non-dense areas with breast cancer risk factors. Lusine Yaghjyan, University of Florida, Gainesville, FL, United States.

A52 Oral contraceptive use and risk of colorectal polyps in a colonoscopy based study in western Washington state. Sheetal Hardikar, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.

Preclinical and Translational Prevention Studies (by Organ Site): Breast Cancer

A53 Benefits of midlife calorie restriction on mammary tumor development in moderately high fat fed mice. Michael Grossmann, Hormel Institute, University of Minnesota, Austin, MN, United States.

Preclinical and Translational Prevention Studies (by Organ Site): Colon and Other Gastrointestinal Cancers

A54 Possible targets of metformin in colorectal cancer. Amikar Sehdev, University of Chicago, Chicago, IL, United States.

Preclinical and Translational Prevention Studies (by Organ Site): Lung Cancer

A55 Mapping the airways: The fate of bronchial epithelium in long term heavy smokers. Kathryn Matney, University of Colorado AMC, Aurora, CO, United States.

Preclinical and Translational Prevention Studies (by Organ Site): Pediatric Malignancies

A56 Metformin targets Rho GTPases to inhibit neuroblastoma cell growth; implications in the treatment of neuroblastoma. Ambrish Kumar, University of South Carolina School of Medicine, Columbia, SC, United States.

A57 ETV6-RUNX1 in urban newborns and young children: Association with Polycyclic Aromatic Hydrocarbon (PAH) DNA adducts in cord blood. Manuela Orjuela, Columbia University, New York, New York, United States.
Preclinical and Translational Prevention Studies (by Organ Site): Prostate and Other Genitourinary Tract Cancers

A58 Aspirin, NSAIDs and risk of prostate cancer: Results from the REDUCE study. Adriana C Vidal, Duke University, Durham, United States.

A59 Dietary Tomato and Lycopene Inhibition of Prostate Carcinogenesis in the TRAMP Model is β,β-Carotene 9,10-oxygenase (BCO2)-Dependent. Jennifer Thomas-Ahner, The Ohio State University, Columbus, Ohio, United States.
Behavioral and Social Science: Alcohol

B01 The role of social support in alcohol consumption and alcohol dependence. Lauren Cole, LSU Health Sciences Center School of Public Health, New Orleans, LA, United States.

B02 Head and neck and esophageal cancers after liver transplant: Results from a multicenter cohort study. Italy, 1997-2010. Diego Serraino, IRCCS CRO, Aviano, Italy.

Behavioral and Social Science: Decision Making

B03 Knowledge, attitudes, and uptake of breast cancer chemoprevention in a multi-ethnic cohort of high-risk women. Meghna Trivedi, Columbia University Medical Center, New York, NY, United States.

Behavioral and Social Science: Diet, Physical Activity, and Energy Balance

B04 Dysregulation of cholesterol homeostasis through loss of CYP27A1 in prostate cancer; Implications for early detection and prevention of over-treatment. Mahmoud Alfaqih, Duke University, Durham, North Carolina, United States.

B05 Randomized pilot study of Project BALANCE: a weight gain prevention intervention for breast cancer patients receiving neoadjuvant chemotherapy. Karen Basen-Engquist, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

B06 Dietary intake in the relation between acculturation and obesity among healthy, Mexican-descent women. Margarita Santiago-Torres, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.

Behavioral and Social Science: Diffusion and Dissemination

B07 Meta-analysis of EGFR and smoking in lung cancer for population health in the global context. Joyce Kusuma, Azusa Pacific University, Azusa, CA, United States.

Behavioral and Social Science: Prevention Behaviors

B08 Meta-analyses of methionine-related polymorphisms and colorectal cancer risk for population health. Carolyn Du, APU, Azusa, California, United States.

Behavioral and Social Science: Quality of Life/Late Effects/Survivorship

B09 Association between cardiorespiratory fitness and quality of life in breast cancer survivors. Christina Dieli-Conwright, University of Southern California, Los Angeles, United States.

B10 Fasting blood glucose and bone mineral density in Latina breast cancer survivors. Lindsey Avery, University of Southern California, Los Angeles, United States.
Behavioral and Social Science: Recruitment/Retention/Adherence Research

B11 An efficient resource to accelerate research into the cause and prevention of breast cancer: The Army of Women. Leah Eshraghi, Dr. Susan Love Research Foundation, Santa Monica, CA, United States.

Behavioral and Social Science: Screening and Early Detection

B12 To screen or not to screen: Examining components of the Extended Parallel Process Model in a tailored-risk communication intervention to promote colorectal cancer screening. Wendy Birmingham, Brigham Young University, Provo, Utah, United States.


B14 Effectiveness of patient navigation for follow-up for abnormal pap tests in Appalachian Kentucky. Mark Dignan, University of Kentucky, Lexington, KY, United States.

Behavioral and Social Science: Tobacco

B15 Second-hand smoke (SHS) and smoking cessation in non-tobacco related cancers. Lawson Eng, Princess Margaret Cancer Centre, Toronto, ON, Canada.

Carcinogenesis: Animal Models of Carcinogenesis and Chemoprevention


B17 The dynamics of gene expression changes observed in a murine model of oral carcinogenesis is associated with specific patterns of pathway activation and drug sensitivity profiles. Jean-Philippe Foy, Cancer Research Center of Lyon, UMR INSERM 1052-CNRS 5286, Centre Léon Bérard, Lyon, France.

B18 Thrombospondin-1 regulates carcinogenesis in an in vivo model of colorectal cancer. Nancy Emenaker, National Cancer Institute, Bethesda, MD, United States.

Carcinogenesis: Clonal Evolution

B19 Malfunction and mutation of airway stem/progenitor cells in preneoplastic bronchial dysplasia. Wilbur H. Franklin, Denver Veterans Affairs Medical Center, Denver, CO, United States.

Carcinogenesis: Oxidative Stress and Carcinogenesis

B20 The cholesterol metabolite, 27-hydroxycholesterol induces hyperplasia in an androgen receptor-dependent manner in normal prostate RWPE-1 cells. Shaneabass Raza, University of North Dakota, Grand Forks, ND, United States.

B21 The effect of mutant Kras associated changes in redox signaling in pancreatic neoplasia. Michelle Schultz, University of Illinois Chicago College of Medicine, Chicago, IL, United States.

Carcinogenesis: Tumor Promotion and Progression

B22 The role of e-cigarette exposure on pulmonary epithelial cell transformation. Stacy Park, UCLA, Los Angeles, CA, United States.
B23 A high-fat diet, but not obesity, promotes tumorigenesis in two mouse models of k-ras-driven lung cancer. Jeffrey Norris, Johns Hopkins University, School of Medicine, Baltimore, MD, United States.

B24 Genomic progression of Barrett's to adenocarcinoma. Marcin Duleba, The Jackson Laboratory, Farmington, CT, United States.

Cell, Molecular, and Tumor Biology: Cancer Genetics/Gene Expression

B25 Association of down-regulation of miR-193b and up-regulation of miR-196a with prognosis in gastric cancer. Wenjie Sun, Tulane University, New Orleans, LA, United States.

B26 Genomic profiles of young onset colorectal cancer tumors are different from older onset CRC. Laura Rozek, University of Michigan School of Public Health, Ann Arbor, MI, United States.

Cell, Molecular, and Tumor Biology: Cell Growth Signaling Pathways

B27 RIP1 maintains DNA integrity and cell proliferation by regulating PGC-1α-mediated mitochondrial oxidative phosphorylation and glycolysis. Wenshu Chen, Lovelace Respiratory Research Institute, Albuquerque, NM, United States.

Cell, Molecular, and Tumor Biology: DNA Methylation/Epigenetics, and Chromatin Regulation

B28 DNA Methylation-based as prediction of therapeutic outcome in serum of patients with breast cancer. Joaquina Martinez-Galan, Hospital Universitario Virgen de las Nieves, Granada, Spain.

B29 Maintenance of a lean phenotype is associated with increased ERβ expression and ERβ gene intron methylation in murine MMTVneu luminal mammary cancer. Emily Rossi, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States.

B30 Different methylation profile of panel of gene between breast cancer patients and control subjects as potential biomarkers for screening breast cancer. Joaquina Martinez-Galan, Hospital Universitario Virgen de las Nieves, Granada, Spain.

B31 Calorie restriction normalizes global microRNA expression by preventing the loss of Dicer expression during mammary tumorigenesis. Kaylyn Devlin, University of Texas at Austin, Austin, TX, United States.

Cell, Molecular, and Tumor Biology: Gene Regulation and Transcriptional Control

B32 Control of nucleotide metabolism by mutant p53 contributes to its gain-of-function activities. Luis Martinez, University of Mississippi Medical Center, Jackson, MS, United States.

B33 Regulation and function of Nrf2-associated long noncoding RNA. Gavin Johnson, Texas A&M Health Science Center, Houston, TX, United States.

Cell, Molecular, and Tumor Biology: Inflammation and Cancer Initiation and Promotion

B34 CD56+ immune cell infiltration is decreased in benign breast lobules with fibrocystic changes. Rushin Brahmbhatt, Mayo Clinic, Rochester, MN, United States.

B35 Cellular competition and metaplastic drive underlie precursors of highly aggressive bladder cancer. Yue Hong, The Jackson Laboratory for Genomic Medicine, Farmington, CT, United States.
Cell, Molecular, and Tumor Biology: Microenvironment

B36 Pyruvate kinase M2 regulates adipocyte differentiation and the expression of enzymes involved in glucose metabolism. Tetsuo Kimura, Weill Cornell Medical College, New York, NY, United States.

B37 Extracellular acid gradient is an energy source in cancer: Acid gradient across plasma membrane in cancer cells can drive robust synthesis of phosphate-bonds. Implication as novel therapeutic target. Gautam Dhar, University of California, Los Angeles, CA, United States.

B38 Regulation of exosome production and cargo by the RNA-binding proteins HuR and TTP in colon cancer cells. Ranjan Preet, University of Kansas Medical Center, Kansas City, KS, United States.

Chemoprevention and Biological Therapies: Anti-inflammatory Therapy

B39 Aspirin modifies immune cell infiltration of the colonic mucosa in Lynch syndrome: a possible mechanism for cancer prevention. Benjamin Hartog, Institute of Genetic Medicine, Newcastle University, Newcastle-Upon-Tyne, United Kingdom.

B40 Low dose aspirin that reduces mortality from lung adenocarcinoma inhibits both platelet COX-1 and the biosynthesis of PGE2. Pierre Massion, Vanderbilt University, Nashville, United States.

Chemoprevention and Biological Therapies: Biological Agents

B41 Intermittent dosing regimens maintain efficacy of several cancer preventing drugs. Vernon Steele, National Cancer Institute, Bethesda, MD, United States.

Chemoprevention and Biological Therapies: Combination Chemoprevention

B42 Nelfinavir potentiates the anti-cancer efficacy of curcumin by subverting endoplasmic reticulum stress toward apoptosis: A promising chemoprevention approach. Debasish Mondal, Tulane University Medical Center, New Orleans, LA, United States.

B43 Targeting multiple cell cycle regulatory points for the prevention of triple negative breast cancer. Powel H. Brown, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

B44 Phyto-chemoprevention of breast cancer: A nutrigenomic study. Somya Shanmuganathan, Sultan Qaboos University, Muscat, Oman.

Chemoprevention and Biological Therapies: Foods and their Bioactive Components

B45 A pilot trial of dietary fish and ω-3 fatty acid supplements in women at high risk for breast cancer. Lisa Yee, The Ohio State University, Columbus, OH, United States.

Chemoprevention and Biological Therapies: Mechanisms of Chemoprevention

B46 The influence of exemestane on breast density in postmenopausal women: A cohort study nested within the NCIC CTG MAP.3 chemoprevention trial. Harriet Richardson, Queen's University, Kingston, Ontario, Canada.

B47 Curcumin C3 ® prevents ultraviolet B radiation-induced epidermal damage in JB6 cells and mouse skin via a Fibroblast growth factor-2-dependent manner. Alok Khandelwal, LSU-Health Shreveport, Shreveport, Louisiana, United States.
B48 Targeting the mTOR pathway for the prevention of ER-negative breast cancer. Abhijit Mazumdar, MD Anderson Cancer Center, Houston, TX, United States.

Chemoprevention and Biological Therapies: Mechanisms of Drug Resistance

B49 Circadian/melatonin disruption by dim light at night drive chemotherapy resistance in breast cancer. Steven Hill, Tulane University School of Medicine, New Orleans, LA, United States.

Chemoprevention and Biological Therapies: Natural Product-based Agents

B50 Differential influence of vitamin D on the tumor promoting eicosanoid PGE2 in women at increased breast cancer risk. Edward Sauter, University of Texas Health Science Center, Tyler, TX.

Chemoprevention and Biological Therapies: New Molecular Targets/Mechanisms of Drug Action

B51 Thioredoxin reductases 1: A key member in metabolism newly identified as prognostic and targetable in non-small cell lung cancer (NSCLC). Yongchang Zhang, Departement of medical oncology, lung cancer and gastrointestinal unit, Hunan Cancer Hospital, Changsha, China.

B52 STAT3 inhibitor HJC0152 prevents ER-negative breast cancer via regulating metabolism. Lili Wang, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Chemoprevention and Biological Therapies: Other

B53 Predicting efficacy of chemopreventive agents in animal tumor assays by statistical modeling. Barbara Dunn, National Cancer Institute, Bethesda, MD, United States.

B54 Current intervention strategies in the NCI PREVENT Cancer Preclinical Drug Development Program. Robert Shoemaker, National Cancer Institute, Bethesda, MD, United States.

B55 Chemoprevention of pancreatic cancer by targeting Kras mutations for apoptosis. Oksana Zagorodna, MD Anderson Cancer Center, Houston, TX, United States.